These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37486312)

  • 21.
    Sharma R; Wang WM; Yusuf S; Evans J; Ramaswami R; Wernig F; Frilling A; Mauri F; Al-Nahhas A; Aboagye EO; Barwick TD
    Radiother Oncol; 2019 Dec; 141():108-115. PubMed ID: 31542317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.
    Haug AR; Rominger A; Mustafa M; Auernhammer C; Göke B; Schmidt GP; Wängler B; Cumming P; Bartenstein P; Hacker M
    J Nucl Med; 2011 Nov; 52(11):1679-83. PubMed ID: 21976529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
    Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
    Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].
    Haug AR; Assmann G; Rist C; Tiling R; Schmidt GP; Bartenstein P; Hacker M
    Radiologe; 2010 Apr; 50(4):349-54. PubMed ID: 20333502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The predictive value of pretherapy [
    Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 68 Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis.
    Hartmann K; Gillman JA; Lazor JW; Ware JB; Weeks JK; Nasrallah IM; Farwell MD; Pantel AR
    Clin Nucl Med; 2024 Jan; 49(1):9-15. PubMed ID: 38048554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
    Hänscheid H; Sweeney RA; Flentje M; Buck AK; Löhr M; Samnick S; Kreissl M; Verburg FA
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1284-8. PubMed ID: 22526964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of
    Daniel KB; de Oliveira Santos A; de Andrade RA; Trentin MBF; Garmes HM
    J Endocrinol Invest; 2021 Oct; 44(10):2195-2202. PubMed ID: 33569721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings.
    Gulpinar B; Peker E; Soydal C; Araz M; Elhan AH
    Br J Radiol; 2020 Feb; 93(1106):20190735. PubMed ID: 31922897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered biodistribution of [
    van de Weijer T; Bemer F; de Vos-Geelen J; Hermans B; Mitea C; van der Pol JAJ; Lodewick T; Wildberger JE; Mottaghy FM
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2420-2427. PubMed ID: 38403723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of
    Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
    J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of [
    Choi SJ; Choi SH; Lee DY; Lee JS; Kim DW; Jang JK
    Eur Radiol; 2022 Jul; 32(7):4628-4637. PubMed ID: 35092473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.